A phase 2 study of trastuzumab in combination with S-1 and cisplatin in first-line human epidermal growth factor receptor (HER)-2-positive advanced gastric cancer.
Su Pin Choo
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Clarinda Wei Ling Chua
No relevant relationships to disclose
Yasuhide Yamada
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Sun Young Rha
No relevant relationships to disclose
Wei Peng Yong
Consultant or Advisory Role - Roche
Other Remuneration - Roche; Taiho Pharmaceutical
Chee Kian Tham
Other Remuneration - Roche; Taiho Pharmaceutical
Matthew Ng
No relevant relationships to disclose
Wai Meng David Tai
No relevant relationships to disclose
Hwee Yong Lim
No relevant relationships to disclose
Iain B. Tan
Other Remuneration - Roche; Taiho Pharmaceutical